Prolonged thrombocytopenia after hematopoietic stem cell transplantation (HSCT) is a
strong risk factor for transplantation-related morbidity and mortality, and no standard …

Thrombocytopenia following allogeneic hematopoietic stem cell transplantation is a usual
complication and can lead to high morbidity and mortality. New strategies, such as the use of …

Persistent thrombocytopenia is a common complication after allogeneic hematopoietic cell
transplantation (HCT). Eltrombopag is an oral thrombopoietin receptor agonist whose …

Persistent cytopenia due to poor graft function (PoGF) is a relatively common complication
which may affect up to 20% of patients undergoing allogeneic hematopoietic stem cell …

Persistent thrombocytopenia is a common complication after allogeneic hematopoietic stem
cell transplantation (allo-SCT). Romiplostim and eltrombopag are the currently available …

Refractory thrombocytopenia is a frequent and severe complication after haploidentical
allogeneic hematopoietic stem cell transplantation (haplo-HSCT) and lacks effective …

Thrombocytopenia after allogeneic hematopoietic stem cell transplantation (allo-SCT) can
pose significant problems in management of patients. Eltrombopag is a small-molecule …

This retrospective study assessed the effectiveness of eltrombopag (EPAG), a
thrombopoietin receptor agonist, in the treatment of poor graft function (PGF) following an …

Hematopoietic cell transplantation (HCT) is a well-established procedure that has become a
therapeutic mainstay for various hematological conditions. Prolonged thrombocytopenia …

Background Thrombocytopenia remains a life-threatening late complication of HCT with an
incidence of 5–20%. Currently, there is no approved drug for the treatment of persistent …